Fortrea (NASDAQ:FTRE) Issues Earnings Results, Beats Estimates By $0.06 EPS

Fortrea (NASDAQ:FTRE) announced its quarterly earnings results on Thursday. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06, FiscalAI reports. The firm had revenue of $691.50 million for the quarter, compared to the consensus estimate of $671.57 million. Fortrea had a positive return on equity of 10.72% and a negative net margin of 3.18%.

Here are the key takeaways from Fortrea’s conference call:

• Fortrea raised and narrowed its 2026 outlook, now expecting revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million, reflecting improved execution and confidence in its return-to-growth strategy.
• Third-quarter adjusted EBITDA rose 14.4% year over year to $58 million, with margin expanding 120 basis points to 8.4% as portfolio mix, cost controls, and efficiency initiatives more than offset higher compensation investments.
• Demand trends improved, with $773 million in net new business awards, a 1.12 times book-to-bill ratio, stronger biotech bookings, and increasing biopharma RFP activity. Management said the broader pipeline and improving market recovery support future growth, although no 2027 guidance was provided.
• Fortrea completed its acquisition of Worldwide Clinical Trials’ Early Phase Services business, expanding its network to more than 570 beds and adding in-house bioanalytical and safety-lab capabilities that management expects to broaden its addressable market and support future profitability.
• Fortrea recorded a cumulative $558 million backlog adjustment, reducing reported backlog to $7.3 billion. Management said the adjustment reflects inactive studies and work no longer expected to be delivered and does not affect current revenue recognition or near- and medium-term planning, but it highlights uncertainty in the long-term backlog.

Fortrea Trading Down 10.7%

FTRE stock traded down $2.78 during trading on Thursday, hitting $23.10. The company had a trading volume of 3,425,850 shares, compared to its average volume of 1,547,397. Fortrea has a 52-week low of $8.55 and a 52-week high of $26.16. The company has a 50 day simple moving average of $20.12 and a 200-day simple moving average of $15.70. The firm has a market capitalization of $2.20 billion, a P/E ratio of -25.24, a PEG ratio of 0.57 and a beta of 1.93. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 1.98.

Analyst Upgrades and Downgrades

FTRE has been the topic of a number of research reports. Citigroup raised their price target on Fortrea from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Evercore restated an “outperform” rating on shares of Fortrea in a research note on Wednesday, July 29th. Barclays upgraded Fortrea from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $22.00 to $23.00 in a research report on Tuesday, October 6th. Truist Financial upped their target price on shares of Fortrea from $19.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Fortrea from a “hold” rating to a “buy” rating and raised their target price for the stock from $20.00 to $25.00 in a report on Thursday, October 15th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Fortrea currently has an average rating of “Hold” and an average target price of $22.80.

Fortrea News Roundup

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Fortrea reported third-quarter adjusted earnings of $0.28 per share, above consensus estimates ranging from $0.22 to $0.24 and up from $0.12 a year earlier. Revenue totaled $691.5 million, surpassing the $671.6 million analyst forecast. Fortrea Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The quarterly performance indicates stronger-than-expected execution and year-over-year earnings growth, which could support the investment case if Fortrea can sustain momentum in subsequent quarters. Fortrea Reports Third Quarter 2026 Results
• Neutral Sentiment: Despite the earnings beat, Fortrea continued to report a negative net margin of 3.18%, highlighting that profitability remains an issue even as adjusted quarterly earnings improve. Fortrea Quarterly Results
• Negative Sentiment: Fortrea revised its full-year 2026 earnings guidance. The change appears to have disappointed investors, with the market treating the updated outlook as more important than the third-quarter beat. The guidance revision raises concerns about the company’s expected earnings trajectory for the remainder of the year. Fortrea Revises Full-Year 2026 Earnings Guidance
• Negative Sentiment: The immediate decline in FTRE suggests investors were positioned for a stronger outlook and are concerned that the revised guidance may limit near-term upside, despite the company exceeding third-quarter estimates. Fortrea Shares Drop After Q3 Results

Insider Transactions at Fortrea

In other Fortrea news, CEO Anshul Thakral sold 99,869 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $19.16, for a total value of $1,913,490.04. Following the transaction, the chief executive officer directly owned 316,797 shares in the company, valued at $6,069,830.52. This represents a 23.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.73% of the stock is currently owned by company insiders.

About Fortrea

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.